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Abstract: Introduction: Type 2 diabetes (T2D) and cardiovascular disease (CVD) risk associate with
ferritin and percent transferrin saturation (%TS) levels. However, increased risk has been observed at
levels considered within the “normal range” for these markers.
Objective: To define normative ferritin and %TS levels associated with T2D and CVD risk.
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Methods: Six-monthly ferritin, %TS and hemoglobin levels from 1,277 iron reduction clinical trial
participants with CVD (peripheral arterial disease, 37% diabetic) permitted pair-wise analysis using
Loess Locally Weighted Smoothing plots. Curves showed continuous quantitative ferritin, hemoglobin
(reflecting physiologic iron requirements), and %TS (reflecting iron transport and sequestration) levels
over a wide range of values. Inflection points in the curves were compared to ferritin and %TS levels
indicating increased T2D and CVD risk in epidemiologic and intervention studies.
Results: Increasing ferritin up to about 80 ng/mL and %TS up to about 25% TS corresponded to increasing hemoglobin levels, and minimal T2D and CVD risk. Displaced Loess trajectories reflected
lower hemoglobin levels in diabetics compared to non-diabetics. Ferritin levels up to about 100 ng/mL
paralleled proportionately increasing %TS levels up to about 55%TS corresponding to further limitation of T2D and CVD risk. Ferritin levels over 100 ng/mL did not associate with hemoglobin levels
and coincided with increased T2D and CVD risk.
Conclusions: Recognition of modified normal ranges for ferritin from about 15 ng/mL up to about 80100 ng/mL and %TS from about 15% up to about 25-55% may improve the value of iron biomarkers
to assess and possibly lower T2D and CVD risk.
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INTRODUCTION
Diabetes is associated with bidirectional abnormalities of
glucose and iron metabolism [1-5]. Meta-analyses of observational studies have shown that ferritin levels in the general
population predict type 2 diabetes (T2D) and gestational
diabetes mellitus (GDM) risk [6-11]. A longitudinal epidemiologic study showed dose-over-time relationships between
elevated ferritin levels and increased mortality from diabetes
and other age-related diseases [12]. Podmore and colleagues
reported the predictive value of measures of iron status
for subsequent diabetes risk [13]. These investigators
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documented continuous linear dose-related associations between ferritin levels and increased T2D risk in men and
women with highly significant differences across ferritin
quintiles. Continuously increasing hazard ratios began at
ferritin levels above about 100 ng/mL, a level generally considered to be within the normal range. Quintile boundaries
placed rising risk in the second quintile for males having low
and high cut points of 68 ng/mL and 117 ng/mL respectively, and in the fourth risk quintile for women having cut
points of 73 ng/mL and 121 ng/mL respectively. In contrast,
reduced T2D risk with higher percent transferrin saturation
(%TS) levels was observed in women at a cutoff approximating 45%TS. This association diminished above 50%TS
and was lost at a cutoff above 55%TS. These findings were
consistent with progressively reduced capacity for transferrin
binding of excess iron or redox-active non-transferrin bound
iron (NTBI) at %TS levels above about 50-55% [13, 14]. A
© 2017 Bentham Science Publishers
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similar trend in men did not reach statistical significance
possibly due to overall higher ferritin levels in men [14-16].
We observed that higher ferritin levels correlated with
mortality during a prospective randomized clinical trial of
iron reduction in primarily males with cardiovascular disease
(CVD, peripheral arterial disease, VACSP 410) [17] along
with increased levels of inflammatory markers: TNF alpha
(receptor 1), IL6 and hsCRP [18, 19]. Significantly improved
disease outcomes related to lower ferritin levels [17, 20, 21]
and with increasing %TS levels in the range of 25-50%TS
[21]. Mean ferritin levels in participants in CSP 410 at entry
were about 122 ng/mL and iron reduction targeted ferritin
levels of 60 ng/mL [17]. Ferritin levels in participants having
no mortality, or non-fatal myocardial infarction or stroke,
over 6-years of follow-up averaged 76 ng/mL [17]. In a participating institution sub-study, the mean ferritin level corresponding to mortality was 132.5 ng/mL while the mean ferritin in those with no mortality was 82.6 ng/mL [18, 19].
These steep dose-effect levels approximated ferritin levels
associated with reduced morbidity and increased longevity
observed in other population studies [20, 22-25], as well as
threshold levels of ferritin and protective %TS levels observed by for T2D risk by Podmore and associates [13].
These epidemiologic and clinical trial associations suggested revision of normative values for ferritin and %TS
levels, common measures of iron metabolism, considered
indicative of the transition from low to increased disease
risk. Similarities in iron biomarker levels associated with
T2D risk [13, 15] and adverse vascular disease outcomes
[17, 21] suggested that examination of graded biomarker
levels during iron reduction would provide further information on quantitative relationships between these biomarkers
of iron metabolism and disease risk.
This report demonstrates quantitative relationships between a wide range of levels of ferritin, %TS and hemoglobin (representing physiologic iron) obtained by direct clinical measurement using Loess plots [26] to display a transition from physiologic to pathologic markers of iron metabolism predictive of adverse clinical outcomes. We reported
previously the utility of Loess methodology to characterize
racial variation in red cell and iron homeostasis [27]. Our
present findings clarify normative ferritin and %TS levels as
measures of iron metabolism predictive of lower disease
risk.
MATERIALS AND METHODS
The Iron and Atherosclerosis Study, FeAST, VA Cooperative Study Program # 410 (CSP 410); a prospective,
randomized, controlled single-blinded clinical trial of iron
reduction; used graded phlebotomy based on ferritin levels
(Trial Registration: www.clinicaltrials.gov, Identifier
NCT00032357) [27-29] to test the hypothesis that improved clinical outcomes might be achieved in subjects
with established CVD by reducing iron stores to levels
typical of children and pre-menopausal women (about 25 to
60 ng/mL). The Consort Diagram [28] and methodological
details of study protocols; informed consent, randomization
and intervention procedures; outcome assessment and study
administration have been reported [28-30]. Institutional
Review Boards (IRBs) at each of the 24 participating hos-
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pitals and a national IRB approved the protocol. Consenting (98.8% male) patients over age 21 (average age 67)
with stable CVD (peripheral arterial disease) were computer randomized by diabetes and smoking status, age, ferritin level, HDL/LDL cholesterol ratio, and medical center
[28-30]. Thirty-seven percent of the 1,277 subjects had a
clinical diagnosis of diabetes at entry. This study was designed to optimize opportunity to detect an effect of follow-up ferritin levels on the primary outcome, all-cause
mortality, and the secondary outcome, death plus non-fatal
myocardial infarction and stroke. Patients were required to
have stable CVD for the past 6 months, no disorder of iron
metabolism including iron deficiency or hemochromatosis,
no malignancy within the past 5 years, hematocrit of >35%,
ferritin level of <400 ng/mL, and creatinine <3.0 mg/dL
[28-30]. Serum ferritin levels up to 400 ng/mL, encountered commonly in practice [12], were similar for diabetics
and non-diabetics (see results section). Because diabetes
was a randomization variable, equivalent numbers of diabetics and non-diabetics were randomized to iron reduction
versus control groups. The use of calibrated phlebotomy
based on ferritin levels (ml blood to be removed = (ferritin
level-25) X10) for iron reduction provided a wide range of
ferritin, %TS and hemoglobin values observed in laboratory test panels obtained at 6-monthly intervals during six
years of observation. Ferritin and %TS levels reported here
represent the 6-monthly (maximum) levels measured during follow-up used to calculate the need for further phlebotomy. For purposes of this report, quantitative data at
entry were examined for normality using the Shapiro-Wilk
test [31] and found to be not normally distributed. Thus,
quantitative data are presented below as medians with 25th
and 75th percentiles. Statistical significance between
groups was tested using the Wilcoxon test [32].
Loess Locally Weighted Scatter Smoothing Plot analysis
[26] was used to detect interrelationships between these variables. This method permits construction of a smooth curve in
order to visualize relationships between two variables over a
continuum not otherwise recognizable within large populations [33-35]. Inflection point relationships between two
variables of interest allow identification of subpopulations
within a larger clinical trial population with unique characteristics associated with graded risk of adverse clinical outcomes [36, 37]. Measures of interest included relationships
between ferritin, %TS reflecting iron transport and sequestration, and hemoglobin levels reflecting physiologic iron
status. Loess methodology has been used to show relationships between individual laboratory variables and clinical
outcomes in studies of diabetes [36-39] and CVD [27, 40,
41]. The present study plotted relationships between ferritin
and hemoglobin levels (8388 paired samples, Fig. 1), between %TS and hemoglobin levels (8371 paired samples,
Fig. 2) and between ferritin and %TS levels (8371 paired
samples, Fig. 3). Loess curves were examined for inflections
below or above which adverse clinical events were less or
more likely to occur. Relevance of observed inflection points
to clinical outcomes was based on outcomes from clinical
trial findings [17, 21, 28] as well as epidemiologic studies
assessing iron biomarker levels and risk of T2D and CVD
[12, 13, 16].
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Fig. (1). Loess smoothing plots of 8388 paired values of hemoglobin and ferritin in diabetic and non-diabetic participants during the
iron reduction trial, CSP 410. The range of values is depicted in the
axes of the figure. Vertical arrows approximate inflection points
associated with the limits of hemoglobin iron requirement, and
altered T2D and CVD risk.
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Fig. (3). Loess plots of 8371 paired ferritin and %TS values in diabetic and non-diabetic participants during the iron reduction trial,
CSP 410. The range of values is depicted in the axes of the figure.
Rising curves overlap with an inflection point marked by the lefthand vertical arrow at about 25%TS and about 80 ng/mL ferritin
(similar to values shown in figures 1 and 2). The right-hand vertical
arrow marks a second inflection point at about 55%TS and 100
ng/mL of ferritin.

RESULTS
The FeAST study included 1,277 entrants, 473 of whom
were diabetic and 804 non-diabetic at entry. Levels of ferritin, %TS and hemoglobin found at entry are expressed here
as medians with 25th and 75th percentiles in parentheses. Median levels of ferritin of 103 ng/mL (61 ng/mL, 170 ng/mL)
and 103 (58, 168) ng/mL, (p=0.681); and median levels of
%TS were 23.4% (18.7%, 30.1%) and 24.7% (18.8%,
30.8%), (p=0.141) were similar at entry for diabetics and
non-diabetics respectively. Median entry levels of hemoglobin were slightly but statistically significantly lower in diabetics compared to non-diabetics: 14.5 g/dL (13.5 g/dL, 15.3
g/dL) versus 14.8 g/dL (13.9 g/dL, 15.7 g/dL), (p<0.001).
Loess plot trajectories for diabetic and non-diabetic participants were similar but displaced for diabetics as shown in
figures 1 and 2 owing to lower hemoglobin levels in diabetics.

Fig. (2). Loess plots of 8371 paired values of hemoglobin and %TS
in diabetic and non-diabetic participants during the iron reduction
trial, CSP 410. The range of values is depicted in the axes of the
figure. The vertical arrow shown here at about 20%TS approximates the inflection point (of 20-25%TS) representing transport
iron for erythropoiesis.

Fig. (1) shows Loess smoothing plots for hemoglobin and
ferritin paired values. Levels of both increase in parallel up
to an inflection point at ferritin levels approximating 80-100
ng/mL reflecting a possible mean upper limit for the physiologic “normal range” (represented by hemoglobin levels)
for both measures. Loess curves for diabetics and nondiabetics were roughly parallel but displaced downward in
diabetics as predicted by the significantly lower hemoglobin
levels in diabetic participants. The inflection point for the
hemoglobin level may be interpreted as occurring at a
somewhat lower ferritin level in diabetics compared to nondiabetics. However, ferritin levels below about 80-100
ng/mL followed a similar trajectory in diabetics and non-
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diabetics. Ferritin levels above the transition at about 80-100
ng/mL lacked physiologic correspondence to increasing hemoglobin levels, an effect that was exaggerated in diabetics
and possibly contributory to “anemia” in certain diabetics
[42].
Fig. (2) shows the Loess plots of paired hemoglobin and
%TS levels. As in Fig. (1), these plots also were roughly
parallel but displaced downward in diabetics. The inflection
point for hemoglobin levels depicted in Fig. (2) occurred at
about 20%TS in both diabetics and non-diabetics. Levels
plateaued above about 25%TS and followed roughly similar
trajectories in relation to hemoglobin levels in diabetics and
non-diabetics throughout the range of values in this data set.
Fig. (3) shows Loess plots of paired ferritin and %TS
levels which increase synchronously with overlapping curves
in diabetics and non-diabetics up to levels of about 55%TS.
The plateau above about 25%TS, the presumed cutoff for
physiologic levels of transport iron for erythropoiesis represented by the %TS level, is similar to that in Fig. (2). Curves
flatten but continue to overlap as levels of both rise in proportion to each other for ferritin levels up to about 100
ng/mL and %TS levels up to about 55%TS. However, curves
for diabetics versus non-diabetics diverge at ferritin levels
above about 100 ng/mL and %TS levels above about 55%.
Above these levels, dissociation of these measures appeared
in which a further increase in ferritin levels is accompanied
by a proportionate rise in %TS in non-diabetics while a less
proportionate ferritin/%TS response occurred in diabetics.
DISCUSSION
Loess plots for diabetic and non-diabetic cohorts differed
because of slightly lower hemoglobin values in diabetics
related presumably to “anemia of chronic disease” occurring
in some diabetics [42]. However, inflection points in relation
to hemoglobin levels occurred in both diabetic and nondiabetic cohorts for ferritin levels at about 80-100 ng/mL,
and for %TS levels at about 25% TS (Figs. 1 and 2, respectively). Increasing ferritin levels up to these inflection points
suggest increasing physiologic incorporation of iron into
hemoglobin.
Data presented in Fig. (1) suggest that ferritin levels approximating 80-100 ng/mL represent an upper normal limit
of physiologic levels of body iron as related to corresponding hemoglobin levels. Ferritin levels over the 80-100 ng/mL
range appear to lack physiologic correspondence with hemoglobin levels. Thus, normative values for the serum ferritin
may range from the commonly accepted lower limit of less
than about 15 ng/mL to an upper limit of about 80-100
ng/mL as observed in this study. This threshold ferritin level
coincides with levels associated with increased T2D risk
observed epidemiologically [13] as well as adverse outcomes
observed in clinical trial data [17, 21].
Fig. (2) shows proportionately increasing hemoglobin
and %TS levels up to about 20-25%TS. Rising %TS levels
gradually plateau above an inflection point of about 25% in
relation to corresponding hemoglobin levels. Transferrin
saturation levels below about 20-25% may be consistent with
transport of iron as holotransferrin for erythropoiesis [14].
Levels above about 25%TS imply a possible switch to incor-
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poration of iron in physiologic excess (or possibly redoxactive NTBI) onto transferrin [14].
The proportionate increase in ferritin and %TS values
shown in Figure 3 up to ferritin levels of about 80 ng/mL and
%TS levels of about 25% suggests strict physiologic correspondence or compensation of these functionally different
proteins representing balance between ferritin and transferrin
as they interact to maintain optimal (compensated) iron homeostasis [14] associated with minimal disease risk [13, 17,
21]. The curves flatten above ferritin levels of about 80
ng/mL and %TS levels above about 25% but then increase
proportionately up to about 100 ng/mL of ferritin of and
about 50-55%TS. These relationships suggest sustained
compensation by an increase in %TS as related to increasing
ferritin levels. Podmore and colleagues [13] also observed
apparent clinical compensation for increasing ferritin levels
with increasing %TS levels up to about 50-55%TS which
appeared to protect against T2D risk. The transition from
physiologic to apparently de-compensated (disproportionately increasing) levels above about 50-55%TS in women
was associated with increased T2D risk in that study [13].
We also noted a similar inflection point in our male participants with CVD at about 25%TS (Figs. 2 and 3). The present
data suggest a transition from presumably protective to potentially toxic %TS levels above a range of about 25-55%TS
in males (Figs. 2 and 3). Progressive iron loading may exceed the capacity for physiologic compensation by transferrin that may be most efficient when ferritin levels remain
below about 80-100 ng/mL [17, 21]. Iron biomarker relationships shown in Figures 2 and 3 corresponding closely to the
epidemiologic findings of Podmore and colleagues [13] for
their observed hazard ratios for ferritin and %TS for T2D
risk. The apparent functional dissociation of ferritin and
%TS above these levels suggests a testable hypothesis that
transferrin may become occupied increasingly with potentially toxic NTBI at ferritin levels considered previously to
be normal [14, 43-45].
Differing functions and regulatory control of ferritin as
compared to %TS levels may also explain the positive
association of ferritin levels with the inflammatory markers,
TNF alpha, IL6 and hsCRP, [18, 19, 43] as well as the
negative association of these inflammatory markers with
%TS levels [42]. In accord with these findings, Podmore and
colleagues also recorded that lower ferritin levels and higher
%TS associate with lower hsCRP levels [13]. Side-by-side
comparison of quantitative %TS data reported here coincides
with clinical outcome data reported in epidemiologic [13]
and clinical trial outcome [21] data. Protective effects appear
to exist for %TS levels up to about 50-55% both diabetes
risk [13] and CVD outcomes [21].
REVISED NORMAL RANGES FOR IRON STATUS
AND LONGEVITY
The revised normal ranges for these biomarkers of iron
metabolism suggested here bear striking resemblance to
other estimates of disease risk in relation to increasing ferritin and %TS levels. Population mean ferritin levels vary
considerably by age, race and sex while %TS levels appear
to be relatively stable [20, 21, 27]. Mean ferritin levels up to
approximately 60-70 ng/mL in the late teens in males and
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females associate with low disease risk [17, 23-25]. Population levels in males increase at a rate of about 4 to 5 ng/mL
per year and plateau at a mean of about 140-150 ng/mL associated with increasing disease risk by middle-age [20].
Cross-sectional measures of ferritin decline gradually with
increasing age to range at about 80-100 ng/mL suggesting
that such lower levels select for greater longevity [20, 24,
25] as illustrated in CSP 410 outcomes data [17]. Low risk
mean ferritin levels below about 50 ng/mL in premenopausal women rise after menopause to plateau at approximately 80-100 ng/mL about 30 years earlier in women
compared to men [20]. The increase in ferritin levels above
this threshold associate with increased post-menopausal disease risk in women [46]. Occurrence of ferritin levels in this
range at an earlier age in women correspond to their increased risk for T2D above this threshold [13]. Higher ferritin levels relate to increasingly impaired beta cell function,
insulin resistance and metabolic abnormalities characterizing
diabetes [5, 47, 48].
Ferritin levels below about 80-100 ng/mL relate to minimal disease and maximum longevity observed in other studies [17, 20, 22-25]. Individuals in the elderly Framingham
Heart Study cohort having a mean age of 75 (age range 6893) but lacking a clinical disease diagnosis had mean ferritin
levels of 86 ng/mL whereas members of the same elderly
cohort having a clinical disease diagnosis had a slightly
higher mean ferritin level of 94 ng/mL [22]. Percent TS levels in the Framingham Heart Study cohort were lower in
individuals without a clinical diagnosis, 25%TS, compared
to individuals having a clinical disease diagnosis, 35%TS.
Based on data shown in Figure 3, 25%TS would be considered within the low risk range and 35%TS, while higher,
would remain in the compensated range. Data from a cohort
of males from the Mediterranean region of Europe over age
80 having relatively low morbidity and mortality had mean
ferritin levels of 68 ng/mL [23]. These levels were significantly lower than levels found in a male population of similar age from The Netherlands having significantly greater
morbidity associated with mean ferritin levels of 137 ng/mL.
Adjusted mean %TS levels were 20% in the healthier Mediterranean population versus 34% in the sicker Northern
European population. Based on our findings, the healthier
Mediterranean population having mean %TS levels of 20%
would be within the low risk range while the higher risk
Northern Europeans of the same age having mean %TS levels of 35%, while slightly higher, would remain in the compensated range. Residents of the Mediterranean region are
known to have a lower risk of T2D [49], vascular disease
and malignancy [23]. These estimates resemble NHANES III
data showing a similar pattern for ferritin levels in freeliving older age individuals [20].
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mean ferritin level for the total cohort at entry was 301
ng/mL. Levels remained unchanged during follow-up in control subjects but declined to a mean of 36 ng/mL (p<0.001)
in subjects randomized to dietary iron restriction. Iron reduction was associated with a significant reduction in the primary study endpoint, p<0.01, and significantly reduced risk
of doubling of the serum creatinine, p<0.02.
Ogawa, et al [25] reported clinical outcome data from a
cohort of patients on chronic hemodialysis, 21% of whom
had diabetic nephropathy. Ferritin levels between about 30
ng/mL and 80 ng/mL were associated with significantly improved long-term survival (p=0.013) compared to survival
with higher or lower ferritin levels and hemoglobin status.
Strong continuous statistical associations exist between
ferritin levels and insulin resistance (IR) measured typically
by the Homeostasis Model Assessment of Insulin Resistance
(HOMA-IR) assay [51-54]. Correlations between IR and
ferritin levels above about 99 ng/mL in men and above about
86 ng/mL in women have been reported [50]. Kim et al [54]
showed significant positive statistical associations between
levels of insulin, fasting glucose and HOMA-IR with ferritin
levels above 98 ng/mL in post-menopausal women (p<0.001
for each comparison). Relationships between iron measures
and HOMA-IR were tracked longitudinally in a cohort of
otherwise healthy non-diabetic women followed from premenopause to one-year post-menopause [55]. During menopausal transition, fasting glucose (p=0.05) ferritin (p<0.01)
and HOMA-IR (p=0.022) increased significantly. Mean premenopausal ferritin levels were 69.5 ng/mL and mean postmenopausal ferritin levels 128.8 ng/mL, resembling low versus increased risk levels observed in the present and other
studies [20,22,23]. Improved IR with removal of a single
unit of blood (500 mL, estimated to reduce ferritin levels by
about 50 ng/mL in a healthy individual) reinforces the concept that IR risk may be a continuum related to the ferritin
level [56].
Relationships between iron measures and T2D risk
[57,58] are relevant to vulnerable populations predisposed
metabolically to diabetes associated with overall increased
ferritin levels [21,27,58-60]. Living at high altitude correlates with both reduced diabetes risk [61] along with lower
ferritin levels [62]. Treatment of diabetes with the oral hypoglycemic agent, metformin, significantly reduces risk of diabetic co-morbidities [63-70]. The anti-diabetic properties of
metformin may be linked to the metal binding properties of
this drug [71]. A 3-month course of metformin reduced ferritin levels by about 50% (p<0.001) and improved insulin
resistance in a cohort of women with polycystic ovary syndrome [72].
LIMITATIONS OF THIS STUDY

REVISED NORMAL RANGES FOR IRON MEASURES AND DIABETES RISK
The validity of the revised normal values for measures of
iron status reported here is supported by several studies of
T2D risk. A prospective randomized interventional trial in
T2D examined effects of rigorous dietary iron restriction
(total n = 191, evaluable n = 170) on development of end
stage renal disease requiring transplantation or all-cause
mortality over a mean follow-up of about 4 years [50]. The

CSP 410 focused on clarification of the role of iron excess in the pathogenesis of CVD that may be potentially
linked to multiple factors that were not investigated in this
clinical trial. Free-living CVD patients with and without diabetes likely have various co-morbidities or more advanced
disease associated with higher ferritin levels than are represented in this cohort [73]. Elevated ferritin levels may relate
to increase in iron stores, inflammatory response, or a combination of both. The plots obtained from the present partici-
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pants may not be characteristic of the general population.
Loess curves reported here were derived from a population
consisting almost entirely of males. Curves derived from a
population of females may also differ from those obtained in
CSP 410. Measures of hepcidin, NTBI [74-76], glycated
hemoglobin, insulin resistance, inflammation and possibly
other variables were not available in this study. T2D risk
may also be attributable to socio-economic factors, environmental contaminants [77-79] or Western Lifestyles [80].
These require further investigation of their effects on iron
biomarkers and associated iron metabolism.
STRENGTHS OF THIS STUDY
Ferritin levels at entry to CSP 410 were a randomization
variable considered a “signal” of iron metabolism conveying
prognostic information. Ferritin levels at entry and intent-totreat ferritin levels during follow-up were interpreted at face
value to determine the amount of blood to be withdrawn by
phlebotomy without attempting to differentiate between
acute phase and non-acute phase levels. Strengths that render
data on iron biomarkers suitable for the present analysis include study’s prospective, randomized single-blinded design,
and longitudinal analysis of a wide range of levels of the
variables of interest. Iron reduction was based on levels of
the primary variable of interest (the serum ferritin level) as
modified with randomization to calibrated phlebotomy [17,
21]. Ferritin levels in this study are observed commonly in
the general population and were subject to experimental
variation [17] as well as natural variation in free-living populations [17, 20]. Diabetes status was also a randomization
variable; similar numbers of diabetics and non-diabetics
were randomized to iron reduction as compared to control
[27-30]. Ferritin and %TS levels reported here were similar
between diabetic and non-diabetic entrants while hemoglobin levels were significantly lower in diabetics. Loess methodology identified break points in a continuum of ferritin
and %TS levels that corresponded to clinical risk [13, 17,
21]. Cut points in Loess curves may reflect an apparent transition from physiologic to pathologic iron biomarker levels
that appeared to be similar between participants with or
without T2D. Thus, the demonstrated quantitative relationships for ferritin and %TS levels that distinguish physiologic
from non-physiologic ferritin levels of these biomarkers or
iron metabolism may facilitate clinical correlation of observations on iron-mediated pathways and risk of T2D [81-83],
its complications [84-86] and its co-morbidities [87-90]. Iron
biomarker values reported here might be extrapolated to comorbidities of diabetes besides CVD. For example, malignancy may have a similar hypothetical pathophysiologic
narrative, i.e., damage to cells and tissues caused by ironcatalyzed oxygen free radical generation [24, 91]. CSP 410
data reported previously showed reduced risk of new visceral
malignancy (p=0.036), and all-cause and cancer-specific
mortality (p=0.009) with randomization to iron reduction
[92]. Mean follow-up ferritin levels in entrants not developing cancer as compared to those developing cancer were 76.4
ng/mL versus 127.1 ng/mL respectively (p=0.017). These
ferritin levels also correspond to lower versus higher risk
values as suggested by the present report. Additionally, ferritin levels below about 100 ng/mL are recommended for

Zacharski et al.

optimal management of diseases of iron excess by the
American Association for the Study of Liver Disease [92].
CONCLUSION
The wide range of putatively “normal” serum ferritin
levels, 30-300 ng/mL in men and 15-200 ng/mL in women, a
10-fold variation, represent extreme variations that do not
resemble the range of normal values for other laboratory
metabolic measures [2, 24]. Revised normal values as reflected by relationships between ferritin, %TS and hemoglobin observed in the present study also associate with epidemiologic and clinical trial data predicting favorable clinical
outcomes. Optimal (minimum risk) serum ferritin levels appear to range from a low of about 15 ng/ml to about 80-100
ng at an upper limit. Data analyzed here for %TS levels resemble the range of normal as accepted commonly having a
lower limit below about 15% and an upper limit of about
55%. We suggest that %TS levels up to about 25% may reflect iron transport for erythropoiesis. Ferritin in relation to
%TS levels ranging between about 25% and 55% may reflect compensation by transferrin scavenging of iron or
NTBI up to ferritin levels of about 100 ng/mL. Ferritin and
%TS levels within these ranges appear to associate with
lower T2D [13] and CVD risk [21].
LIST OF ABBREVIATIONS
CSP 410

=

VA Cooperative Studies Program #410

CVD

=

cardiovascular disease

FeAST

=

The Iron and Atherosclerosis Study, CSP
410

GDM

=

gestational diabetes mellitus

HOMA-IR

=

Homeostasis Model Assessment of Insulin Resistance

HDL

=

High density lipoprotein cholesterol

hsCRP

=

high sensitivity C-reactive protein

IRB

=

Institutional review board

LDL

=

low density lipoprotein cholesterol

IL6

=

Interleukin 6

Loess

=

Locally weighted scatter plot smoothing

NHANES

=

National Health And Nutrition Examination Survey

NTBI

=

Non-transferrin bound iron

TNF

=

Tumor necrosis factor

TS

=

transferrin saturation

T2D

=

Type 2 diabetes

VA

=

Veterans Administration

AUTHOR CONTRIBUTIONS
L.R.Z. and R.G.D drafted the manuscript, G.S. and B.K.
C. performed the statistical analyses and prepared the figures. L.R.Z., G.S., B.K.C. and R.G.D. contributed to writing
and editing the manuscript, and approved the final manuscript for submission.

Iron Measures, Diabetes and Cardiovascular Risk

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Current Diabetes Reviews, 2017, Vol. 13, No. 0

[13]

Not applicable.
HUMAN AND ANIMAL RIGHTS

[14]

No Animals/Humans were used for studies that are base
of this research.

[15]

CONSENT FOR PUBLICATION
Not applicable.

[16]

CONFLICT OF INTEREST
The authors confirm that this article content has no conflict of interest.

[17]
[18]

ACKNOWLEDGEMENTS
The Cooperative Studies Program (CSP 410) of the Department of Veterans Affairs Office of Research and Development, Clinical Science Research & Development Service
supported The Iron and Atherosclerosis Study (FeAST). The
opinions expressed are those of the authors and not those of
the government of the United States or the Department of
Veterans Affairs.
REFERENCES
[1]
[2]
[3]
[4]

[5]
[6]
[7]
[8]
[9]

[10]

[11]

[12]

Swaminathan S, Fonesca VA, Alam MG, Shah SV. The role of iron
in in diabetes and its complications. Diabetes Care 2007; 30: 19261933.
Simcox JA, McClain DA. Iron and Diabetes Risk. Cell Metab
2013; 17: 329-341.
Hansen JB, Tonnesen MF, Madsen AN, et al. Divalent metal transporter 1 regulates iron-mediated ROS and pancreatic beta cell fate
in response to cytokines. Cell Metab 2012;16:449-61.
Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is prospectively associated with insulin resistance and glucose
intolerance over a 7-year follow-up period: the CODAM study.
Acta Diabetol 2015;52: 337-348.
Fernández-Real JM, McClain D, Manco M. Mechanisms linking
glucose homeostasis and iron metabolism toward the onset and
progression of type 2 diabetes. Diabetes Care 2015; 3: 2169-2176.
Orban E, Schwab S, Thorand B, Huth C. Association of iron indices and type 2 diabetes: a meta-analysis of observational studies.
Diabetes Metab Res Rev 2014; 30: 372-394.
Fu S, Li F, Zhou J, Liu, Z. The relationship between Body iron
status, iron intake and gestational diabetes: A systematic review
and meta-analysis. Medicine (Baltimore) 2016; 95: e2383.
Zhao Z, Li S, Liu G, et al. Body iron stores and heme-iron intake in
relation to risk of type 2 diabetes: a systematic review and metaanalysis. PLoS One 2012; 7: e41641.
Bao W, Rong Y, Rong S, Liu, L. Dietary iron intake, body iron
stores, and the risk of type 2 diabetes: a systematic review and
meta-analysis. BMC Med 2012; 10: 119. doi: 10.1186/1741-701510-119.
Khambalia AZ, Aimone A, Nagubandi P, et al. High maternal iron
status, dietary iron intake and iron supplement use in pregnancy
and risk of gestational diabetes mellitus: a prospective study and
systematic review. Diabet Med 2015; Dec 16. doi:
10.1111/dme.13056.
Kunutsor SK, Apekey TA, Walley J, Kain K. Ferritin levels and
risk of type 2 diabetes mellitus: an updated systematic review and
meta-analysis of prospective evidence. Diabetes Metab Res Rev
2013; 29: 308-18.
Ellervik C, Marott JL, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG. Total and cause-specific mortality by moderately and

[19]
[20]
[21]

[22]

[23]

[24]
[25]

[26]
[27]
[28]
[29]

[30]

[31]
[32]
[33]

[34]

7

markedly increased ferritin concentrations: general population
study and metaanalysis. Clin Chem 2014;60:1419-1428.
Podmore C, Meidtner K, Schulze MB, et al. The Association of
Multiple Biomarkers of Iron Metabolism and Type 2 Diabetes: The
EPIC-InterAct Study. Diabetes Care 2016;39: doi 10.2337/dc150257.
Elsayed ME, Sharif MU, Stack AG. Transferrin saturation: A
body iron biomarker. Adv Clin Chem 2016;75:71-97. doi:
10.1016/bs.acc.2016.03.002. Epub 2016 May 6.
Jung CH, Lee MJ, Hwang JY, et al. Elevated serum ferritin level is
associated with the incident type 2 diabetes in healthy Korean men:
a 4 year longitudinal study. PLoS One. 2013; 8: e75250. doi:
10.1371/journal.pone.0075250. eCollection 2013.
Aregbesola A, Voutilainen S, Virtanen JK, Mursu J, Tuomainen
TP. Body iron stores and the risk of type 2 diabetes in middle-aged
men. Eur J Endocrinol 2013;169:247-53. doi: 10.1530/EJE-130145.
Zacharski LR, Shamayeva G, Chow, B.K. Effect of controlled
reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J 2011;162: 949-957.e1.
DePalma RG, Hayes VW, Chow BK, et al. Ferritin levels, inflammatory biomarkers and mortality in peripheral arterial disease: A
sub-study of the Iron (Fe) and Atherosclerosis Study (FeAST)
Trial. J Vasc Surg 2010;51: 1498-1503.
DePalma RG, Hayes VW, Cafferata HT, et al. Cytokine signatures
in atherosclerotic claudicants. J Surg Res 2003;111: 215-221.
Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis
of NHANES III data. Am Heart J 2000;140: 98-104.
Zacharski LR, Shamayeva G, Chow BK, DePalma RG. Racial
Differences in Iron Measures and Outcomes Observed during an
Iron Reduction Trial in Peripheral Arterial Disease. J Health Care
Poor Underserved 2015; 26: 243-59. doi: 10.1353/hpu.2015.0026.
Fleming DJ, Jacques PF, Tucker KL, et al. Iron status of the freeliving, elderly Framingham Heart Study cohort: an iron-replete
population with a high prevalence of elevated iron stores. Am J
Clin Nutr 2001; 73:638-46.
Buijsse B, Feskens EJ, Moschandreas J, et al. Oxidative stress, and
iron and antioxidant status in elderly men: differences between the
Mediterranean south (Crete) and northern Europe (Zutphen). Eur J
Cardiovasc Prev Rehabil 2007;14: 495-500.
Silva B, Faustino P. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim Biophys Acta 2015; 1852:1347-59. doi: 10.1016/j.bbadis.2015.03.011.
Ogawa C, Tsuchiya K, Kanda F, Maeda T. Low levels of serum
ferritin lead to adequate hemoglobin levels and good survival in
hemodialysis patients. Am J Nephrol 2014; 40: 561-70. doi:
10.1159/000370317. Epub 2015 Jan 10.
Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. J Amer Stat Assn
1988;83: 596–610.
Zacharski LR, Shamayeva G, Chow BK, DePalma RG. Racial
health disparities, and variant red cell and iron homeostasis.
J Health Care Poor Underserved 2016; 27:741-61.
Zacharski LR, Chow BK, Howes PS, et al. Reduction of Iron
Stores and Cardiovascular Outcomes in Patients with Peripheral
Arterial Disease. JAMA 2007; 297: 603-10.
Zacharski LR, Chow, BK, Howes PS, Shamayeva G, Lavori PW.
Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA Cooperative Study #410: The Iron
and Atherosclerosis Study. Am Heart J 2004; 148: 386-92.
Zacharski LR, Chow B, Lavori PW, et al. The Iron (Fe) and atherosclerosis study (FeAST). I. A pilot study of reduction of body iron
stores in atherosclerotic peripheral vascular disease. VA Cooperative Study #410. Am Heart J 2000; 139:337-345.
Ghasemi A, Zahediasl S. Normality Tests for Statistical Analysis:
A Guide for Non-Statisticians. Int J Endocrinol Metab
2012;10:486-9.
Wilcoxon F. Individual Comparisons by Ranking Methods. Biometrics Bulletin 1945; 1:80-83.
Cleophas TJ, Zwinderman AH. The Assessment of Non-Linear
Effects in Clinical Research. Pharmacology & Pharmacy 2012; 3:
139-147. http://dx.doi.org/10.4236/pp.2012.32021Accessed: February 14, 2016
Loess
methodology:
http://www.statisticshowto.com/lowesssmoothing/ Accessed: February 14, 2016

8
[35]
[36]
[37]

[38]

[39]

[40]

[41]

[42]
[43]

[44]
[45]
[46]

[47]

[48]
[49]

[50]
[51]

[52]

[53]
[54]

[55]

Current Diabetes Reviews, 2017, Vol. 13, No. 0
Loess
regression
curve
fitting:http://www.statsdirect.com/help/content/nonparametric_met
hods/loess.htm Accessed: February 14, 2016
Zhu J, Xie J. Nonparametric Variable Selection for Predictive
Models and Subpopulations in Clinical Trials. J Biopharm Stat.
2015; 25: 781–794. doi: 10.1080/10543406.2014.920861
Loess regression graphics and clinical trial data display:
https://support.sas.com/documentation/cdl/en/statug/63033/HTML/
default/viewer.htm#statug_loess_sect002.htm Accessed: February
14, 2016
Warram JH, Scott LJ, Hanna LS, et al. Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship
with
hyperglycemia.
Diabetes
2000;
49:
94-100.
http://dx.doi.org/10.2337/diabetes.49.1.94.
Nirantharakumar K, Hemming K, Narendran P, Marshall T, Coleman JJ. A Prediction Model for Adverse Outcome in Hospitalized
Patients With Diabetes. Diabetes Care 2013; 36: 3566-3572.
http://dx.doi.org/10.2337/dc13-0452.
Nissen SE, Murat Tuzcu EM, Libby P, et al, for the CAMELOT
Investigators. Effect of Antihypertensive Agents on Cardiovascular
Events in Patients With Coronary Disease and Normal Blood Pressure. The CAMELOT Study: A Randomized Controlled Trial.
JAMA 2004; 292: 2217-2225. doi:10.1001/jama.292.18.2217.
Kulloa IJ, Baileyc KR, Kardiad SLR, Mosleye TH Jr, Boerwinklef
E, Turnera ST. Ethnic differences in peripheral arterial disease in
the NHLBI Genetic Epidemiology Network of Arteriopathy
(GENOA) study. Vasc Med 2003; 8: 237–242.
Angelousi A, Larger E. Anaemia, a common but often unrecognized risk in diabetic patients: a review. Diabetes Metab 2015;
41:18-27. doi: 10.1016/j.diabet.2014.06.001. Epub 2014 Jul 17.
Lee DH, Zacharski LR, Jacobs DR, Jr. Comparison of the serum
ferritin and percentage of transferrin saturation as exposure markers
of iron-driven oxidative stress-related disease outcomes. Am Heart
J 2006;151: 1247.e1-7.
Ponka P, Beaumont C, Richardson DR. Function and regulation of
transferrin and ferritin. Semin Hematol 1998; 35:35-54.
Adams PC, Reboussin DM, Press RD, et al. Biological variability
of transferrin saturation and unsaturated iron binding capacity. Am
J Med 2007; 120: 999e1–999e7.
Brand JS, van der Schouw YT, Onland-Moret NC, et al. Age at
menopause, reproductive life span, and type 2 diabetes risk: results
from the EPIC-InterAct study. Diabetes Care 2013; 36: 1012-9.
doi: 10.2337/dc12-1020. Epub 2012 Dec 10.
Bonfils L, Ellervik C, Friedrich N, et al. Fasting serum levels of
ferritin are associated with impaired pancreatic beta cell function
and decreased insulin sensitivity: a population-based study. Diabetologia 2015;58: 523-533.
Hansen JB, Moen IW, Mandrup-Poulsen T. Iron: the hard player in
diabetes pathophysiology. Acta Physiol (Oxf) 2014;210:717-32.
de Lorgeril M, Salen P. The Mediterranean diet to prevent type 2
diabetes and its complications. Chapter 31 in: Preedy VR, Watson
RR, The Mediterranean Diet: An Evidence-Based Approach. Elsevier, Amsterdam, 2015; pp 337-342.
Facchini FS1, Saylor KL. A low-iron-available, polyphenolenriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 2003; 52:1204-9.
Pham NM, Nanri A, Yi S, et al. Serum ferritin is associated with
markers of insulin resistance in Japanese men but not in women.
Metabolism 2013; 62: 561-7. doi: 10.1016/j.metabol.2012.07.025.
Epub 2012 Oct 27.
Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. Metabolism
2011; 60: 414–420.
Alnahal AA, Tahan M, Fathy A, Fathy T. Effect of deferoxamine
therapy on insulin resistance in end-stage renal disease patients
with iron overload. Saudi J Kidney Dis Transpl 2014; 25: 808-13.
Kim MK, Chon SJ, Jung YS, et al. The Relationship between Serum Ferritin Levels and Insulin Resistance in Pre- and Postmenopausal Korean Women: KNHANES 2007-2010. PLoS One 2016;
11: e0157934. doi: 10.1371/journal.pone.0157934. eCollection
2016. Erratum in: PLoS One. 2016;11(7):e0160300.
Kim C, Nan B, Kong S, Harlow S. Changes in iron measures over
menopause and associations with insulin resistance. J Women’s
Health 2012; 21: 872-7. doi: 10.1089/jwh.2012.3549. Epub 2012
Jun 25.

Zacharski et al.
[56]
[57]

[58]
[59]
[60]

[61]

[62]
[63]

[64]

[65]
[66]

[67]
[68]

[69]

[70]

[71]
[72]
[73]
[74]

[75]

[76]
[77]

Facchini FS. Effect of phlebotomy on plasma glucose and insulin
concentrations. Diabetes Care 1998; 21: 2190.
Huth C, Beuerle S, Zierer A, et al. Biomarkers of iron metabolism
are independently associated with impaired glucose metabolism
and type 2 diabetes: the KORA F4 study. Eur J Endocrinol 2015;
173: 643-53. doi: 10.1530/EJE-15-0631. Epub 2015 Aug 20.
Kershaw KN, Pender AE. Racial/Ethnic Residential Segregation,
Obesity, and Diabetes Mellitus. Curr Diab Rep 2016; 16:108.
Baldwin HJ, Green AE, Spellar KM, Arthur PJ, Phillips HG, Patel
JV. Tipping the balance: Haemoglobinopathies and the risk of diabetes. World J Diabetes 2016; 7: 8-13. doi: 10.4239/wjd.v7.i1.8.
Zimmermann MB, Fucharoen S, Winichagoon P, et al. Iron metabolism in heterozygotes for hemoglobin E (HbE), alphathalassemia 1, or beta-thalassemia and in compound heterozygotes
for HbE/beta-thalassemia. Am J Clin Nutr 2008; 88: 1026-31.
Woolcott OO, Castillo OA, Gutierrez C, Elashoff RM, Stefanovski
D, Bergman RN. Inverse association between diabetes and altitude:
a cross-sectional study in the adult population of the United States.
Obesity 2014; 22: 2080-90. doi: 10.1002/oby.20800. Epub 2014
May 28.
Cook JD, Boy E, Flowers C, Daroca Mdel C. The influence of
high-altitude living on body iron. Blood 2005; 106: 1441-6. Epub
2005 May 3.
Fung CS, Wan EY, Wong CK, Jiao F, Chan AK. Effect of metformin monotherapy on cardiovascular diseases and mortality: a
retrospective cohort study on Chinese type 2 diabetes mellitus patients. Cardiovasc Diabetol 2015; 14: 137. doi: 10.1186/s12933015-0304-2.
Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in postpolypectomy patients without diabetes: a multicentre double-blind,
placebo-controlled, randomised phase 3 trial. Lancet Oncol 2016;
17: 475-83. doi: 10.1016/S1470-2045(15)00565-3. Epub 2016 Mar
3.
Chan AT. Metformin for cancer prevention: a reason for optimism.
Lancet Oncol 2016; 17: 407-9. doi: 10.1016/S14702045(16)00006-1. Epub 2016 Mar 3.
Wei M, Liu Y, Wang C, et al. The need for differentiating diabetesspecific mortality from total mortality when comparing metformin
with insulin regarding cancer survival. Acta Diabetol 2016 Oct 28.
[Epub ahead of print].
Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL. Metformin
and prostate cancer mortality: a meta-analysis. Cancer Causes Control. 2016; 27:105-13. doi: 10.1007/s10552-015-0687-0.
Chan KM, Kuo CF, Hsu JT, et al. Metformin confers risk reduction
for developing hepatocellular carcinoma recurrence after liver resection. Liver Int 2016; Oct 24. doi: 10.1111/liv.13280. [Epub
ahead of print].
Sun GE, Wells BJ, Yip K, et al. Gender-specific effects of oral
hypoglycaemic agents on cancer risk in type 2 diabetes mellitus.
Diabetes Obes Metab 2014; 16: 276-83. doi: 10.1111/dom.12231.
Epub 2013 Dec 5.
Xu H, Chen K, Jia X, et al. Metformin Use Is Associated With
Better Survival of Breast Cancer Patients With Diabetes: A MetaAnalysis.
Oncologist
2015;
20:
1236-44.
doi:
10.1634/theoncologist.2015-0096. Epub 2015 Oct 7.
Logie L, Harthill J, Patel K, et al. Cellular responses to the metalbinding properties of metformin. Diabetes 2012; 61: 1423-33. doi:
10.2337/db11-0961. Epub 2012 Apr 9.
Behradmanesh S, Ranjbar Omrani GH, Ghazanfarpour F, Baradaran A. Effect of metformin on serum ferritin level in women with
polycystic ovary syndrome.
Red Crescent Med J 2011;13:487-92. Epub 2011 Jul 1.
Jenq CC, Hsu CW, Huang WH, Chen KH, Lin JL, Lin-Tan DT.
Serum ferritin levels predict all-cause and infection-cause 1-year
mortality in diabetic patients on maintenance hemodialysis. Am J
Med Sci 2009; 337:188-94. doi: 10.1097/MAJ.0b013e31818d8bbe.
de Swart L, Hendriks JC, van der Vorm LN, et al. Second international round robin for the quantification of serum non-transferrinbound iron and labile plasma iron in patients with iron-overload
disorders. Haematologica 2016;101: 38-45.
Lee DH, Liu DY, Jacobs DR Jr, et al. Common presence of nontransferrin-bound iron among patients with type 2 diabetes. Diabetes Care 2006; 29: 1090-1095.
Aljwaid H, White DL, Collard KJ, Moody AJ, Pinkney JH. Nontransferrin-bound iron is associated with biomarkers of oxidative

Iron Measures, Diabetes and Cardiovascular Risk

[78]
[79]
[80]
[81]

[82]

[83]
[84]

[85]
[86]

stress, inflammation and endothelial dysfunction in type 2 diabetes.
J
Diabetes
Complications.
2015;29:943-9.
doi:
10.1016/j.jdiacomp.2015.05.017. Epub 2015 Jun 3.
La Merrill MA. The economic legacy of endocrine-disrupting
chemicals.
Lancet
Diabetes
Endocrinol
2016;
doi.org/10.1016/52213-8587(16) 30279-0.
Franks PW, McCarthy MI. Exposing the exposures responsible for
type 2 diabetes and obesity. Science 2016; 354: 69-73.
Trasande L, Lampa E, Lind L, Lind PM. Population attributable
risks and costs of diabetogenic chemical exposures in the elderly. J
Epidemiol Community Health doi:10.1136/jech-2016-208006.
Ghio AJ, Schreinemachers DM. Heme Oxygenase Activity Correlates with Serum Indices of Iron Homeostasis in Healthy Nonsmokers.
Biomark
Insights
2016;
11:49-54.
doi:
10.4137/BMI.S36226. eCollection 2016.
Andrews M, Leiva E, Arredondo-Olguín M. Short repeats in the
heme oxygenase 1 gene promoter is associated with increased levels of inflammation, ferritin and higher risk of type-2 diabetes mellitus. J Trace Elem Med Biol 2016; 37: 25-30. doi:
10.1016/j.jtemb.2016.06.001. Epub 2016 Jun 2.
Tiwari S, Ndisang JF. The heme oxygenase system and type-1
diabetes. Curr Pharm Des 2014; 20:1328-37.
Abraham NG, Junge JM, Drummond GS. Translational Significance of Heme Oxygenase in Obesity and Metabolic Syndrome.
Trends
Pharmacol
Sci
2016;
37:
17-36.
doi:
10.1016/j.tips.2015.09.003. Epub 2015 Oct 26.
Pagnin E, Maiolino G, Calò LA. Heme oxygenase-1 in type 2 diabetes: from cell first-line defense to early marker of diabetic nephropathy. Minerva Med 2016; 107: 123-4.
Negi G, Nakkina V, Kamble P, Sharma SS. Heme oxygenase-1, a
novel target for the treatment of diabetic complications: focus on
diabetic peripheral neuropathy. Pharmacol Res 2015; 102: 158-67.
doi: 10.1016/j.phrs.2015.09.014. Epub 2015 Oct 22.

Current Diabetes Reviews, 2017, Vol. 13, No. 0
[87]

[88]

[89]

[90]

[91]
[92]

[93]

9

Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R,
Fiore CE. The relationship between inhibitors of the Wnt signalling
pathway (sclerostin and Dickkopf-1) and carotid intima-media
thickness in postmenopausal women with type 2 diabetes mellitus.
Diab
Vasc
Dis
Res
2014;
11:
48-52.
doi:
10.1177/1479164113510923. Epub 2013 Nov 12.
Ma Y, Hébert JR, Balasubramanian R, et al. All-cause, cardiovascular, and cancer mortality rates in postmenopausal white, black,
Hispanic, and Asian women with and without diabetes in the
United States: the Women's Health Initiative, 1993-2009. Am J
Epidemiol 2013;178: 1533-41. doi: 10.1093/aje/kwt177. Epub
2013 Sep 17.
Stroh M, Swerdlow RH, Zhu H. Common defects of mitochondria
and iron in neurodegeneration and diabetes (MIND): a paradigm
worth exploring. Biochem Pharmacol 2014; 88: 573-83. doi:
10.1016/j.bcp.2013.11.022. Epub 2013 Dec 19.
Cheung CL, Cheung TT, Lam KS, Cheung BM. High ferritin and
low transferrin saturation are associated with pre-diabetes among a
national representative sample of U.S. adults. Clin Nutr 2013; 32:
1055-60. doi: 10.1016/j.clnu.2012.11.024. Epub 2012 Dec 28.
Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996;
5: 19-36.
Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk
after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100: 9961002. doi: 10.1093/jnci/djn209. Epub 2008 Jul 8.
Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS.
American Association for the Study of Liver Diseases. Diagnosis
and management of hemochromatosis: 2011 practice guideline by
the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328-43.

